| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ART.11038 |
| P698 | PubMed publication ID | 12847688 |
| P2093 | author name string | Simone Dorsch | |
| Susanne Modrow | |||
| Antje Knöll | |||
| Hartwig W Lehmann | |||
| Philipp Von Landenberg | |||
| P2860 | cites work | Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H) | Q24558202 |
| Mycoplasma penetrans bacteremia and primary antiphospholipid syndrome | Q24647693 | ||
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA) | Q28243715 | ||
| Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus | Q28261335 | ||
| Molecular mimicry between non-self, modified self and self in autoimmunity | Q28266657 | ||
| The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 | ||
| Human parvovirus B19 infection: its relationship with systemic lupus erythematosus. | Q33328900 | ||
| Acute parvovirus B19 infection in connection with a flare of systemic lupus erythematodes in a female patient | Q33330476 | ||
| Seroprevalence of parvovirus B19 NS1-specific IgG in B19-infected and uninfected individuals and in infected pregnant women | Q33330672 | ||
| The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity | Q33340668 | ||
| Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome | Q33341518 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice | Q33491319 | ||
| Possible induction of systemic lupus erythematosus by human parvovirus | Q33564763 | ||
| Molecular mimicry and autoimmunity. | Q33806107 | ||
| Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review | Q33982832 | ||
| A viral phospholipase A2 is required for parvovirus infectivity | Q34101246 | ||
| Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients | Q34435380 | ||
| Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group | Q34523084 | ||
| Immune response to B19 parvovirus and an antibody defect in persistent viral infection | Q35815343 | ||
| Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H). | Q35822651 | ||
| Cellular transcription factors that interact with p6 promoter elements of parvovirus B19. | Q38300496 | ||
| Systemic lupus erythematosus-associated catastrophic antiphospholipid syndrome occurring after typhoid fever: a possible role of Salmonella lipopolysaccharide in the occurrence of diffuse vasculopathy-coagulopathy | Q40638900 | ||
| Human parvovirus B19 and blood products | Q40914889 | ||
| There is no association between polymyalgia rheumatica and acute parvovirus B19 infection | Q43053218 | ||
| Chronic human parvovirus B19 infection in rheumatic disease of childhood and adolescence | Q44118097 | ||
| Systemic lupus erythematosus associated with acute parvovirus B19 infection | Q44274608 | ||
| Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus | Q45050925 | ||
| Antibodies to the Nonstructural Protein of Parvovirus B19 in Persistently Infected Patients: Implications for Pathogenesis | Q45195559 | ||
| Persistence of parvovirus B19 DNA in synovium of patients with haemophilic arthritis | Q45879548 | ||
| Parvovirus B19 infection in pregnancy: quantitative viral DNA analysis using a kinetic fluorescence detection system (TaqMan PCR). | Q53315230 | ||
| Beta2GP-I in the anti phospholipid (Hughes') syndrome--from a cofactor to an autoantigen--from induction to prevention of antiphospholipid syndrome. | Q54483428 | ||
| Recurrent granulocytic aplasia as clinical presentation of a persistent parvovirus B19 infection | Q68077832 | ||
| Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy | Q69354191 | ||
| Chronic bone marrow failure due to persistent B19 parvovirus infection | Q70184002 | ||
| Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy | Q73233286 | ||
| Quantitative evidence for persistence of human parvovirus B19 DNA in an immunocompetent individual | Q73383797 | ||
| Human parvovirus B19 infection in patients with systemic lupus erythematosus | Q73635920 | ||
| Evidence for persistence of human parvovirus B19 DNA in bone marrow | Q73870588 | ||
| Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction | Q73936945 | ||
| Antibodies to parvovirus B19 non-structural protein are associated with chronic but not acute arthritis following B19 infection | Q74205367 | ||
| Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome | Q74376610 | ||
| Evidence for persistence of parvovirus B19 DNA in livers of adults | Q74460725 | ||
| Presence and significance of human parvovirus B19 DNA in synovial membranes and bone marrow from patients with arthritis of unknown origin | Q77448535 | ||
| Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients | Q77451463 | ||
| P433 | issue | 7 | |
| P921 | main subject | rheumatism | Q684924 |
| P304 | page(s) | 1939-1947 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Arthritis and Rheumatism | Q23929027 |
| P1476 | title | Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection | |
| P478 | volume | 48 |
| Q35926536 | APhL antibody ELISA as an alternative to anticardiolipin test for the diagnosis of antiphospholipid syndrome. |
| Q34120947 | Advances in human B19 erythrovirus biology |
| Q38885685 | Anti-phospholipid Antibodies and Smoking: An Overview |
| Q47727907 | Antigenicity analysis of human parvovirus B19-VP1u protein in the induction of anti-phospholipid syndrome |
| Q51057447 | Antiphospholipid antibodies in HIV-positive patients. |
| Q36832529 | Antiphospholipid antibodies in response to infection |
| Q38308870 | Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity |
| Q38084889 | Diagnosis and management of infectious complications of childhood rheumatic diseases |
| Q43985866 | Different patterns of disease manifestations of parvovirus B19-associated reactive juvenile arthritis and the induction of antiphospholipid-antibodies |
| Q40360576 | Does parvovirus infection have a role in systemic lupus erythematosus? |
| Q92239610 | Environmental Triggers of Autoreactive Responses: Induction of Antiphospholipid Antibody Formation |
| Q34808812 | Exacerbating effects of human parvovirus B19 NS1 on liver fibrosis in NZB/W F1 mice |
| Q62573683 | Human Parvovirus B19: Molecular Virology, Clinical Features, Prevalence, Diagnosis and Control |
| Q38996997 | Human Parvoviruses |
| Q34652025 | Human parvovirus B19 NS1 protein aggravates liver injury in NZB/W F1 mice |
| Q34776941 | Human parvovirus B19 induced apoptotic bodies contain altered self-antigens that are phagocytosed by antigen presenting cells. |
| Q33902693 | Human parvovirus B19 nonstructural protein NS1 enhanced the expression of cleavage of 70 kDa U1-snRNP autoantigen |
| Q50736394 | Increased expression and secretion of interleukin-6 in human parvovirus B19 non-structural protein (NS1) transfected COS-7 epithelial cells. |
| Q33383620 | Increased expression of Matrix Metalloproteinase 9 in liver from NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein |
| Q37352874 | Infections and the antiphospholipid syndrome |
| Q42006546 | Interaction of parvovirus B19 with human erythrocytes alters virus structure and cell membrane integrity |
| Q24792864 | Intravenous immunoglobulin treatment of four patients with juvenile polyarticular arthritis associated with persistent parvovirus B19 infection and antiphospholipid antibodies |
| Q42907953 | Severe warm autoimmune haemolytic anaemia due to anti-Jk(a) autoantibody associated with Parvovirus B19 infection in a child |
| Q38266664 | The Etiology of Juvenile Idiopathic Arthritis |
Search more.